The previous guidelines for the management of CVr in the patients with diabetes were published in the European Heart Journal in 2013, but the growing number of CV safety trials in the patients with type 2 DM (T2DM) (Harmony, PIONEER) demonstrated that the use of both glucagon-like peptide-1 receptor agonists (GLP1-RA) and sodium-glucose-transporter 2 (SGLT2) inhibitors is strongly recommended in patients with T2DM with prevalent cardiovascular diseases (CVD) or high/very high CVr and treated with metformin. The gene discussed is GLP1R; the disease is diabetes mellitus.